| Literature DB >> 21376481 |
G Rossi1, C Cornaro, M Battilani, V Pocacqua, S Paltrinieri.
Abstract
Interferon gamma (IFN-γ) plays an important role in cell mediated responses against mutated feline coronavirus strains (FCoV) involved in the pathogenesis of feline infectious peritonitis (FIP). The aim of this study was to establish a combined in silico and in vitro approach to assess feline leukocyte production of IFN-γ in response to selected peptides of the nucleocapside protein (N) of FCoVs. To this aim, we designed, through a bioinformatic approach, 8 potentially immunogenic peptides from the protein N corresponding to sequences of residues 14, 182, 198 detected only in FCoVs from FIP cats (virulent strains), only in FCoVs from healthy cats (avirulent strains) and both in FIP and in healthy cats (mixed strains). The peptides or a sham solution were incubated with whole blood from 16 cats (7 healthy and 9 with chronic diseases other than FIP) and IFN-γ concentration was measured on plasma using an ELISA system. RT-PCR expression of IFN-γ mRNA was also evaluated after incubation of the peptides or a sham solution with whole blood from 4 clinically healthy cats. The mean plasma concentration of IFN-γ in samples incubated with peptides decreased and the expression of IFN-γmRNA did not change compared with the sham solution, except for some cats with chronic diseases (which probably have a "pre-activated" immune response). These cats responded to "avirulent" or "mixed" peptides by increasing the concentration of IFN-γ and the expression of IFN-γ mRNA. The combined approach employed in this study allowed us to identify potentially immunogenic peptides of FCoV N protein that can modulate the production of IFN-γ especially in cats with a "pre-activated" cell mediated response.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21376481 PMCID: PMC7117359 DOI: 10.1016/j.vetmic.2011.02.004
Source DB: PubMed Journal: Vet Microbiol ISSN: 0378-1135 Impact factor: 3.293
Sequences of the peptides designed on the basis of RNA sequences detected in feline coronaviruses from faeces of healthy cats (FECV-like or “non virulent strains”), from tissues of cats with feline infectious peritonitis (FIPV-like or “virulent strains”) or both (FECV/FIPV-like or “mixed strains”).
| Peptide | Sequence | Position | Biotype |
|---|---|---|---|
| P1 | PSKRRGSN | 14–22 | FECV/FIPV |
| P2 | PSKSGRSNS | 14–22 | FECV |
| P3 | SNNQNNVEDTIV | 182–193 | FECV/FIPV |
| P4 | PNNQNNNVDTIV | 182–193 | FIPV |
| P5 | FNNQNNNVEDITIV | 182–194 | FECV |
| P6 | KLGVTDKLRS | 198–207 | FIPV |
| P7 | RLGVTSDNKQ | 198–207 | FECV |
| P8 | KLGVTDKQRS | 198–207 | FECV/FIPV |
Results obtained in native plasma and in plasma added with peptides P1–P8.
| IFN-γ (ng/mL) | |
|---|---|
| Native plasma | 3.21 |
| Plasma + P1 | 3.18 |
| Plasma + P2 | 3.21 |
| Plasma + P3 | 3.18 |
| Plasma + P4 | 3.26 |
| Plasma + P5 | 3.23 |
| Plasma + P6 | 3.15 |
| Plasma + P7 | 3.14 |
| Plasma + P8 | 3.14 |
Individual results recorded in the study: for each cat the concentration of IFN-γ (ng/mL) recorded in the different wells after incubation with sham solution (P0) or with the different peptides (P1–P8) is reported. When available, also the concentration of IFN-γ recorded in plasma before incubation is reported.
| Cat | Status | Plasma | P0 | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | S | 4.12 | 2.49 | 1.41 | 0.66 | 0.20 | 0.15 | ||||
| 2 | S | 0.29 | 6.81 | 4.29 | |||||||
| 3 | H | 1.67 | 0.76 | 0.33 | 0.22 | 0.18 | 8.55 | 2.69 | 1.47 | 1.75 | |
| 4 | H | 0.89 | 0.26 | 0.2 | |||||||
| 5 | H | 7.77 | 4.68 | 3.09 | 1.65 | 0.90 | 0.25 | ||||
| 6 | S | 0.44 | 0.14 | 6.34 | |||||||
| 7 | S | 4.12 | 1.65 | 1.52 | 0.35 | 0.16 | 0.19 | 0.12 | 2.62 | ||
| 8 | H | 1.63 | 1.16 | 0.98 | 0.53 | 0.26 | 0.25 | 0.17 | |||
| 9 | S | 5.04 | 4.00 | 3.06 | 1.98 | 0.98 | 0.48 | ||||
| 10 | H | 0.41 | 0.17 | 6.02 | 3.14 | 2.13 | 2.2 | 0.78 | 0.36 | 0.49 | 0.17 |
| 11 | S | 5.96 | 1.92 | 1.94 | 0.7 | 0.3 | 0.37 | 0.15 | 10.72 | 6.97 | |
| 12 | S | 4.22 | 2.05 | 0.47 | 0.19 | 0.2 | 0.15 | 10.43 | |||
| 13 | S+ | 3.07 | 1.48 | 2.25 | |||||||
| 14 | S | 1.04 | 0.64 | 0.62 | 0.44 | ||||||
| 15 | H+ | 1.39 | 0.57 | 0.47 | 0.6 | ||||||
| 16 | H+ | 3.34 | 1.15 | 0.66 |
R14, R182, R198: residues 14, 182 and 198, respectively. A: avirulent (FECV biotype); V: virulent (FIPV biotype); M: mixed (FECV/FIPV biotype); S: sick; H: healthy; +: anti-FCoV titre > 1:100; in bold: values higher than the reference interval.
Summary of the results of ELISA testing recorded after incubation with sham solution or with peptides (mean ± D.S. and, between parenthesis, median values) and results of statistical analysis.
| IFN-γ (ng/mL) | Wilcoxon test | ||
|---|---|---|---|
| Sham | Peptide | ||
| P1 – R14M ( | 3.50 ± 2.50 (4.12) | 2.49 ± 1.85 (1.97) | |
| P2 – R14A ( | 2.54 ± 1.90 (2.37) | 1.21 ± 0.87 (1.07) | |
| P3 – R182M ( | 3.48 ± 2.52 (4.12) | 1.80 ± 1.95 (1.06) | |
| P4 – R182V ( | 4.14 ± 2.56 (4.12) | 1.30 ± 1.39 (0.67) | |
| P5 – R182A ( | 3.86 ± 2.36 (4.12) | 1.38 ± 2.71 (0.37) | |
| P6 – R198V ( | 2.64 ± 1.99 (3.07) | 0.83 ± 0.96 (0.44) | |
| P7 – R198A ( | 3.23 ± 2.29 (4.12) | 5.15 ± 5.01 (2.61) | |
| P8 – R198M ( | 3.77 ± 2.72 (4.12) | 1.41 ± 2.51 (0.25) | |
P1–P8: number of the peptide; R14, R182, R198: residues 14, 182 and 198, respectively. A: avirulent (FECV biotype); V: virulent (FIPV biotype); M: mixed (FECV/FIPV biotype);
Fig. 1Distribution of individual results after incubation with sham solution or with peptides.
Summary of the RT-PCR results recorded after incubation with sham solution or with peptides.
| Cat A | Cat B | Cat C | Cat D | D | U | I | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | RI | AI | RI | AI | RI | AI | RI | ||||
| P0 – Sham | − | n/a | − | n/a | − | n/a | + | n/a | n/a | n/a | n/a |
| P1 – R14M | − | U | − | U | − | U | + | U | 0/4 | 4/4 | 0/4 |
| P2 – R14A | − | U | − | U | − | U | +/− | D | 1/4 | 3/4 | 0/4 |
| P3 – R182M | +/− | I | − | U | − | U | + | U | 0/4 | 3/4 | 1/4 |
| P4 – R182V | +/− | I | − | U | − | U | +/− | D | 1/4 | 2/4 | 1/4 |
| P5 – R182A | +/− | I | + | I | − | D | +/− | U | 1/4 | 2/4 | 1/4 |
| P6 – R198V | − | U | − | U | − | U | +/− | D | 1/4 | 3/4 | 0/4 |
| P7 – R198A | − | U | + | I | + | I | + | U | 0/4 | 2/4 | 2/4 |
| P8 – R198M | +/− | I | − | U | − | U | + | U | 0/4 | 3/4 | 1/4 |
AI: absolute intensity (i.e. intensity recorded in each lane). RI: relative intensity (i.e. intensity compared with P0). P1–P8: number of the peptide; R14, R182, R198: residues 14, 182 and 198, respectively. A: avirulent (FECV biotype); V: virulent (FIPV biotype); M: mixed (FECV/FIPV biotype); n/a: not applicable; U: unchanged compared with P0; I: increased compared with P0; D: decreased compared with P0